Coronavirus (COVID-19) Clinical Trials

MUSC is meeting the challenge of the novel coronavirus, COVID-19, through research aimed at discovering vaccines, new treatments, and ways to prevent or reduce the spread of the virus.

COVID-19 Study Opportunities

The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina

Recruitment Contact:
Judith Shary

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19

Recruitment Contact:
Angela Millare

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19

Recruitment Contact:
Max Lento

Expanded Access to Convalescent Plasma for the Treatment of Pediatric Patients with COVID-19 

Thank you for your interest is plasma donation.

For information regarding plasma donation or to schedule an appointment to make a donation, please contact:

The Blood Connection (854-429-1700) or the American Red Cross(843-764-2323) by phone or by visiting their websites to learn more.

If you have been tested for COVID-19 and need your test results for your plasma donation appointment, you can access these results by logging into MUSC Health MyChart and accessing the “Health” tab and selecting “Test Results”

If you do not yet have a MyChart account, visit MUSC Health MyChart and click the blue “Create Your Account” button to create one (this can take up to 48 hours).

If do not want to access this information through MyChart or if you cannot locate your COVID-19 lab results in MyChart, you may request your results from the MUSC medical records department at 843-792-3881.

If you were tested for COVID-19 at a non-MUSC facility, please contact your physician or the records department at that facility.

A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared with Remdesivir Plus Placebo in Hospitalized Patients with Severe COVID-19 Pneumonia

Recruitment Contact:
Abigail Grady

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2

Recruitment Contact:
Nicholas Ciappa

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

Recruitment Contact:
April Rasberry

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease (COVID-19)

Recruitment Contact:
Ebony Dawkins Mikell

COVID-19 Vaccine Study

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

The AZD1222 COVID-19 VACCINE Study is researching an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2). The study will see how safe the investigational vaccine is and how well it works.

Are you able to help?

You may be able to take part in the AZD1222 COVID-19 VACCINE Study if you:

  • Are 18 years of age or older.
  • Are in good or stable health. (You may have an underlying medical condition and still take part if your disease is stable.)
  • Have an increased risk of getting COVID-19.
  • Do not have a previously confirmed diagnosis of COVID-19.

Participants will be randomly assigned (by chance) to receive 2 injections of either the investigational vaccine or placebo. A placebo looks like the investigational vaccine but contains no active vaccine. There is twice as much chance of receiving the investigational vaccine than of receiving placebo.

If you take part, you will be in the study for approximately 2 years and will require up to 10 visits to our study center. Additional visits may be required if you develop symptoms of COVID-19 during the study. Your health will be monitored carefully by a team of doctors and nurses throughout the study. The study injections, health assessments, and medical tests related to the study will be provided at no cost to you.

Please contact the study team today if you are interested in joining the AZD1222 COVID-19 VACCINE Study or would like more information. By contacting us, you are under no obligation to take part in the study. We look forward to hearing from you soon.

SCTR / MUSC COVID-19 Biorepository

The Medical University of South Carolina (MUSC) is developing a COVID-19 biorepository which will contain blood, urine, and other bodily fluids along with relevant medical information from individuals evaluated, exposed to, or treated for COVID-19.

Recruitment Contact:

Lauren Card

Healthcare Worker Exposure Response & Outcomes (HERO) Registry

MUSC is participating in the HERO Registry, a large, national clinical research community. Healthcare workers across America may join the registry to share clinical and life experiences to understand the perspectives and problems they face on the COVID-19 pandemic front lines.

Visit the HERO Registry website to learn more and join the registry.

MUSC Contact for questions regarding the HERO Registry:

Elizabeth Szwast

Additional Opportunities

SC logo

View a full list of active COVID-19 research opportunities, including study details and contact information at (Keyword search for coronavirus and COVID-19.)

Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19

Status: Closed

Rapid In-Home SARS-CoV-2 IgG Antibody Testing to Assess Community Level Immunity in Health Care Workers Working in High Risk Exposure Settings

Status: Closed

A Phase II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4 mg/kg Intravenous Tocilizumab in Patients with Moderate to Severe COVID-19 Pneumonia

Status: Enrollment closed

Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease

Status: Enrollment closed